JP2010500037A5 - - Google Patents

Download PDF

Info

Publication number
JP2010500037A5
JP2010500037A5 JP2009524012A JP2009524012A JP2010500037A5 JP 2010500037 A5 JP2010500037 A5 JP 2010500037A5 JP 2009524012 A JP2009524012 A JP 2009524012A JP 2009524012 A JP2009524012 A JP 2009524012A JP 2010500037 A5 JP2010500037 A5 JP 2010500037A5
Authority
JP
Japan
Prior art keywords
peptide
item
composition
cell
pap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009524012A
Other languages
English (en)
Japanese (ja)
Other versions
JP5189094B2 (ja
JP2010500037A (ja
Filing date
Publication date
Priority claimed from US11/836,653 external-priority patent/US8361479B2/en
Application filed filed Critical
Publication of JP2010500037A publication Critical patent/JP2010500037A/ja
Publication of JP2010500037A5 publication Critical patent/JP2010500037A5/ja
Application granted granted Critical
Publication of JP5189094B2 publication Critical patent/JP5189094B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009524012A 2006-08-11 2007-08-10 無差別papcd4t細胞エピトープ Expired - Fee Related JP5189094B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83705306P 2006-08-11 2006-08-11
US60/837,053 2006-08-11
US11/836,653 US8361479B2 (en) 2006-08-11 2007-08-09 Promiscuous PAP CD4 T cell epitopes
US11/836,653 2007-08-09
PCT/US2007/075704 WO2008022030A2 (en) 2006-08-11 2007-08-10 Promiscuous pap cd4 t cell epitopes

Publications (3)

Publication Number Publication Date
JP2010500037A JP2010500037A (ja) 2010-01-07
JP2010500037A5 true JP2010500037A5 (https=) 2011-09-08
JP5189094B2 JP5189094B2 (ja) 2013-04-24

Family

ID=39082999

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009524012A Expired - Fee Related JP5189094B2 (ja) 2006-08-11 2007-08-10 無差別papcd4t細胞エピトープ

Country Status (7)

Country Link
US (2) US8361479B2 (https=)
EP (1) EP2056859B1 (https=)
JP (1) JP5189094B2 (https=)
CA (1) CA2660064C (https=)
ES (1) ES2620740T3 (https=)
PL (1) PL2056859T3 (https=)
WO (1) WO2008022030A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2376923A4 (en) * 2008-12-22 2012-08-15 Children S Res Inst METHOD FOR DETECTING SEPSIS
WO2010119307A1 (en) * 2009-04-14 2010-10-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for stimulating antigen-specific t cell responses using accelerated co-cultured dendritic cells
GB2484058A (en) * 2009-12-01 2012-04-04 Uni Konstanz Prostate cancer DNA vaccine
FR3000263B1 (fr) * 2012-12-21 2015-03-06 Ingenico Sa Detection d'un dispositif transactionnel
WO2017096247A1 (en) * 2015-12-04 2017-06-08 Mayo Foundation For Medical Education And Research Methods and vaccines for inducing immune responses to multiple different mhc molecules
CN110079539B (zh) * 2018-01-25 2022-07-01 上海惠盾因泰生物科技有限公司 前列腺酸性磷酸酶/粒-巨噬细胞集落刺激因子制备方法
IT202000013243A1 (it) 2020-06-04 2021-12-04 Novamont Spa Processo per la purificazione di una miscela di dioli

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552534A (en) 1991-08-22 1996-09-03 The Trustees Of The University Of Pennsylvania Non-Peptide peptidomimetics
US5550251A (en) 1991-12-12 1996-08-27 The Trustees Of The University Of Pennsylvania Alicyclic peptidomimetics
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
CA2394741A1 (en) * 1999-12-21 2001-06-28 Epimmune Inc. Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
CA2497554A1 (en) 2002-09-20 2004-04-01 Dendreon Corporation Immunotherapeutic compositions and methods for the treatment of moderately to well-differentiated cancers
CA2500715A1 (en) 2002-10-03 2004-04-15 Epimmune Inc. Hla binding peptides and their uses

Similar Documents

Publication Publication Date Title
JP2010500037A5 (https=)
US10570387B2 (en) Antigen screening system
Srikiatkhachorn et al. Induction of Th-1 and Th-2 responses by respiratory syncytial virus attachment glycoprotein is epitope and major histocompatibility complex independent
JP2009506762A5 (https=)
JP2019510465A5 (https=)
TR201903223T4 (tr) Reaktivasyonu önlemek üzere bir tüberküloz TB aşısı.
CN106573960A (zh) 用于针对乙型肝炎病毒感染的治疗性接种的合成长肽(slp)
CN113956342B (zh) 一种肿瘤新生抗原多肽及其应用
WO2016054038A1 (en) Use of hla genetic status to assess or select treatment of celiac disease
CN115925820A (zh) 乙型肝炎病毒抗原的胸腺依赖性淋巴细胞抗原表位肽及其应用
Hamrouni et al. Design of multi-epitope peptides containing HLA class-I and class-II-restricted epitopes derived from immunogenic Leishmania proteins, and evaluation of CD4+ and CD8+ T cell responses induced in cured cutaneous leishmaniasis subjects
CN107022006A (zh) 乙型肝炎病毒抗原的胸腺依赖性淋巴细胞抗原表位肽序列
CN110964093A (zh) 原发性肝癌相关抗原的胸腺依赖性淋巴细胞抗原表位肽及其应用
CN116056722A (zh) Sars-cov-2疫苗
Suzuki et al. Identification of murine H2-Dd-and H2-Ab-restricted T-cell epitopes on a novel protective antigen, MPT51, of Mycobacterium tuberculosis
JP2015529219A5 (https=)
Hassebroek et al. A hepatitis B virus core antigen‐based virus‐like particle vaccine expressing SARS‐CoV‐2 B and T cell epitopes induces epitope‐specific humoral and cell‐mediated immune responses but confers limited protection against SARS‐CoV‐2 infection
Dzul-Rosado et al. Immunogenicity of OmpA and OmpB antigens from Rickettsia rickettsii on mononuclear cells from Rickettsia positive Mexican patients
JP2010501160A5 (https=)
JP2012526519A5 (https=)
CN101124335B (zh) 高通量蛋白组学
JP2022535458A (ja) B型肝炎ウイルス特異的なt細胞応答
Liu et al. A mutant HBs antigen (HBsAg) 183–191 epitope elicits specific cytotoxic T lymphocytes in acute hepatitis B patients
Vitalis et al. Using the TAP component of the antigen-processing machinery as a molecular adjuvant
WO2000044775A2 (en) Identification of broadly reactive hla restricted t cell epitopes